• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

5.610 +0.740 (+15.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
TriSalus Life Sciences Reports Second Quarter 2026 Results
August 06, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 29, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
July 16, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 23, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 17, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 16, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 10, 2026
From Schall Law
Via GlobeNewswire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
June 10, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 09, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 03, 2026
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
May 20, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
May 20, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
May 19, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
May 19, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
May 12, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
May 12, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
May 04, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
April 28, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
April 09, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
April 07, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
March 18, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
March 05, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
February 25, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
February 20, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Proposes Public Offering
February 19, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
February 09, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
January 12, 2026
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
December 04, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
November 18, 2025
From TriSalus Life Sciences
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap